Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7121267 | 0.89 | NFE2L2 (0.45) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL4027579 | 0.89 | ALDH1A1 (0.46) | NFE2L2HSD11B1PTGS1APP | |
| SCHEMBL9970459 | 0.86 | NFE2L2 (0.62) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL700052 | 0.80 | NFE2L2 (0.78) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL13766470 | 0.80 | NFE2L2 (0.78) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL22468800 | 0.80 | NFE2L2 (0.78) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL13766558 | 0.80 | NFE2L2 (0.78) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL700051 | 0.80 | NFE2L2 (0.78) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL8068914 | 0.77 | NFE2L2 (0.52) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL1435786 | 0.77 | ALDH1A1 (0.60) | NFE2L2HSD11B1PTGS1APPFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6667346-B2 | Administration of a radioprotective alpha, beta unsaturated aryl sulfone compound to a patient prior to anticancer radiotherapy reduces cytotoxic side effects of radiation on normal cells | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-12-23 | — | — | US | disclosed |